Personalis (PSNL) Competitors

$8.47 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$8.44 -0.03 (-0.35%)

As of 05/22/2026 07:58 PM Eastern

PSNL vs. GRAL, HTFL, DFTX, SGRY, and PGNY

Should you buy Personalis stock or one of its competitors? MarketBeat compares Personalis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Personalis include GRAIL (GRAL), Heartflow (HTFL), Definium Therapeutics (DFTX), Surgery Partners (SGRY), and Progyny (PGNY). These companies are all part of the "healthcare" industry.

How does Personalis compare to GRAIL?

Personalis (NASDAQ:PSNL) and GRAIL (NASDAQ:GRAL) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, profitability, risk, dividends, earnings and analyst recommendations.

Personalis presently has a consensus target price of $11.00, indicating a potential upside of 29.87%. GRAIL has a consensus target price of $67.88, indicating a potential upside of 1.02%. Given Personalis' stronger consensus rating and higher probable upside, analysts clearly believe Personalis is more favorable than GRAIL.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Personalis	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
GRAIL	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

Personalis has higher earnings, but lower revenue than GRAIL. Personalis is trading at a lower price-to-earnings ratio than GRAIL, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Personalis	$69.65M	12.73	-$81.27M	-$1.02	N/A
GRAIL	$147.17M	19.59	-$408.35M	-$10.37	N/A

Personalis has a beta of 1.96, suggesting that its share price is 96% more volatile than the broader market. Comparatively, GRAIL has a beta of 3.03, suggesting that its share price is 203% more volatile than the broader market.

Personalis has a net margin of -148.11% compared to GRAIL's net margin of -253.22%. GRAIL's return on equity of -16.42% beat Personalis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Personalis	-148.11%	-43.52%	-32.92%
GRAIL	-253.22%	-16.42%	-14.34%

In the previous week, Personalis had 2 more articles in the media than GRAIL. MarketBeat recorded 4 mentions for Personalis and 2 mentions for GRAIL. GRAIL's average media sentiment score of 0.95 beat Personalis' score of 0.33 indicating that GRAIL is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Personalis	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
GRAIL	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

61.9% of Personalis shares are owned by institutional investors. 4.2% of Personalis shares are owned by insiders. Comparatively, 1.8% of GRAIL shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Personalis beats GRAIL on 9 of the 16 factors compared between the two stocks.

How does Personalis compare to Heartflow?

Heartflow (NASDAQ:HTFL) and Personalis (NASDAQ:PSNL) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability.

61.9% of Personalis shares are held by institutional investors. 7.7% of Heartflow shares are held by company insiders. Comparatively, 4.2% of Personalis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Personalis has lower revenue, but higher earnings than Heartflow. Heartflow is trading at a lower price-to-earnings ratio than Personalis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heartflow	$176.03M	14.45	-$116.79M	-$3.11	N/A
Personalis	$69.65M	12.73	-$81.27M	-$1.02	N/A

In the previous week, Personalis had 2 more articles in the media than Heartflow. MarketBeat recorded 4 mentions for Personalis and 2 mentions for Heartflow. Personalis' average media sentiment score of 0.33 beat Heartflow's score of -0.05 indicating that Personalis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Heartflow	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Personalis	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Heartflow has a net margin of -58.42% compared to Personalis' net margin of -148.11%. Heartflow's return on equity of 0.00% beat Personalis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heartflow	-58.42%	N/A	-20.02%
Personalis	-148.11%	-43.52%	-32.92%

Heartflow presently has a consensus target price of $37.00, suggesting a potential upside of 25.47%. Personalis has a consensus target price of $11.00, suggesting a potential upside of 29.87%. Given Personalis' stronger consensus rating and higher possible upside, analysts clearly believe Personalis is more favorable than Heartflow.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heartflow	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Personalis	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

Personalis beats Heartflow on 8 of the 15 factors compared between the two stocks.

How does Personalis compare to Definium Therapeutics?

Personalis (NASDAQ:PSNL) and Definium Therapeutics (NASDAQ:DFTX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

61.9% of Personalis shares are held by institutional investors. Comparatively, 27.9% of Definium Therapeutics shares are held by institutional investors. 4.2% of Personalis shares are held by insiders. Comparatively, 2.3% of Definium Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Personalis has a beta of 1.96, meaning that its share price is 96% more volatile than the broader market. Comparatively, Definium Therapeutics has a beta of 2.37, meaning that its share price is 137% more volatile than the broader market.

In the previous week, Definium Therapeutics had 4 more articles in the media than Personalis. MarketBeat recorded 8 mentions for Definium Therapeutics and 4 mentions for Personalis. Personalis' average media sentiment score of 0.33 beat Definium Therapeutics' score of -0.08 indicating that Personalis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Personalis	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Definium Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Personalis presently has a consensus target price of $11.00, indicating a potential upside of 29.87%. Definium Therapeutics has a consensus target price of $37.92, indicating a potential upside of 68.55%. Given Definium Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Definium Therapeutics is more favorable than Personalis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Personalis	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00

Personalis has higher revenue and earnings than Definium Therapeutics. Definium Therapeutics is trading at a lower price-to-earnings ratio than Personalis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Personalis	$69.65M	12.73	-$81.27M	-$1.02	N/A
Definium Therapeutics	N/A	N/A	-$183.79M	-$2.49	N/A

Definium Therapeutics has a net margin of 0.00% compared to Personalis' net margin of -148.11%. Personalis' return on equity of -43.52% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Personalis	-148.11%	-43.52%	-32.92%
Definium Therapeutics	N/A	-100.30%	-69.22%

Summary

Personalis beats Definium Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Personalis compare to Surgery Partners?

Personalis (NASDAQ:PSNL) and Surgery Partners (NASDAQ:SGRY) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, dividends, profitability, earnings, valuation and media sentiment.

In the previous week, Personalis and Personalis both had 4 articles in the media. Surgery Partners' average media sentiment score of 0.34 beat Personalis' score of 0.33 indicating that Surgery Partners is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Personalis	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Surgery Partners	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Surgery Partners has higher revenue and earnings than Personalis. Surgery Partners is trading at a lower price-to-earnings ratio than Personalis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Personalis	$69.65M	12.73	-$81.27M	-$1.02	N/A
Surgery Partners	$3.31B	0.53	-$77.90M	-$0.60	N/A

Surgery Partners has a net margin of -2.28% compared to Personalis' net margin of -148.11%. Surgery Partners' return on equity of 1.04% beat Personalis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Personalis	-148.11%	-43.52%	-32.92%
Surgery Partners	-2.28%	1.04%	0.41%

Personalis has a beta of 1.96, suggesting that its share price is 96% more volatile than the broader market. Comparatively, Surgery Partners has a beta of 1.99, suggesting that its share price is 99% more volatile than the broader market.

61.9% of Personalis shares are owned by institutional investors. 4.2% of Personalis shares are owned by insiders. Comparatively, 2.7% of Surgery Partners shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Personalis currently has a consensus price target of $11.00, suggesting a potential upside of 29.87%. Surgery Partners has a consensus price target of $22.18, suggesting a potential upside of 65.54%. Given Surgery Partners' stronger consensus rating and higher possible upside, analysts clearly believe Surgery Partners is more favorable than Personalis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Personalis	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Surgery Partners	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58

Summary

Surgery Partners beats Personalis on 11 of the 15 factors compared between the two stocks.

How does Personalis compare to Progyny?

Progyny (NASDAQ:PGNY) and Personalis (NASDAQ:PSNL) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings, risk and media sentiment.

94.9% of Progyny shares are owned by institutional investors. Comparatively, 61.9% of Personalis shares are owned by institutional investors. 9.9% of Progyny shares are owned by insiders. Comparatively, 4.2% of Personalis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Progyny currently has a consensus price target of $29.55, suggesting a potential upside of 18.75%. Personalis has a consensus price target of $11.00, suggesting a potential upside of 29.87%. Given Personalis' higher probable upside, analysts plainly believe Personalis is more favorable than Progyny.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Progyny	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92
Personalis	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Progyny had 4 more articles in the media than Personalis. MarketBeat recorded 8 mentions for Progyny and 4 mentions for Personalis. Personalis' average media sentiment score of 0.33 beat Progyny's score of 0.24 indicating that Personalis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Progyny	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Personalis	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Progyny has higher revenue and earnings than Personalis. Personalis is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Progyny	$1.29B	1.51	$58.52M	$0.77	32.31
Personalis	$69.65M	12.73	-$81.27M	-$1.02	N/A

Progyny has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market. Comparatively, Personalis has a beta of 1.96, suggesting that its stock price is 96% more volatile than the broader market.

Progyny has a net margin of 5.23% compared to Personalis' net margin of -148.11%. Progyny's return on equity of 13.34% beat Personalis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Progyny	5.23%	13.34%	9.03%
Personalis	-148.11%	-43.52%	-32.92%

Summary

Progyny beats Personalis on 13 of the 17 factors compared between the two stocks.

Get Personalis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PSNL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PSNL vs. The Competition

Export

Metric	Personalis	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$886.99M	$5.88B	$6.46B	$12.34B
Dividend Yield	N/A	0.72%	2.76%	5.28%
P/E Ratio	-8.30	8.59	21.22	25.66
Price / Sales	12.73	20.97	562.28	86.31
Price / Cash	N/A	8.40	43.49	56.67
Price / Book	3.49	4.20	10.31	7.14
Net Income	-$81.27M	$102.24M	$3.57B	$335.98M
7 Day Performance	20.31%	5.42%	6.43%	4.15%
1 Month Performance	38.85%	0.90%	3.57%	2.54%
1 Year Performance	77.20%	133.78%	34.07%	35.06%

Personalis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count
PSNL Personalis	2.6822 of 5 stars	$8.47 flat	$11.00 +29.9%	+77.2%	$886.99M	$69.65M	N/A	400
GRAL GRAIL	1.4162 of 5 stars	$60.71 +1.8%	$67.88 +11.8%	+67.2%	$2.56B	$147.17M	N/A	1,360
HTFL Heartflow	3.332 of 5 stars	$25.65 -9.4%	$37.00 +44.2%	N/A	$2.44B	$191.42M	N/A	699
DFTX Definium Therapeutics	2.9572 of 5 stars	$20.48 -2.4%	$37.92 +85.2%	+208.2%	$2.09B	N/A	N/A	40
SGRY Surgery Partners	3.716 of 5 stars	$13.92 -0.2%	$22.18 +59.4%	-41.2%	$1.82B	$3.31B	N/A	16,000

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PSNL) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Personalis (PSNL) Competitors

PSNL vs. GRAL, HTFL, DFTX, SGRY, and PGNY

How does Personalis compare to GRAIL?

Summary

How does Personalis compare to Heartflow?

Summary

How does Personalis compare to Definium Therapeutics?

Summary

How does Personalis compare to Surgery Partners?

Summary

How does Personalis compare to Progyny?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PSNL vs. The Competition

Personalis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Personalis (PSNL) Competitors

PSNL vs. GRAL, HTFL, DFTX, SGRY, and PGNY

How does Personalis compare to GRAIL?

Do analysts recommend PSNL or GRAL?

Which has better earnings and valuation, PSNL or GRAL?

Which has more volatility and risk, PSNL or GRAL?

Is PSNL or GRAL more profitable?

Does the media refer more to PSNL or GRAL?

Do insiders and institutionals believe in PSNL or GRAL?

Summary

How does Personalis compare to Heartflow?

Do institutionals & insiders believe in HTFL or PSNL?

Which has better valuation & earnings, HTFL or PSNL?

Does the media prefer HTFL or PSNL?

Is HTFL or PSNL more profitable?

Do analysts rate HTFL or PSNL?

Summary

How does Personalis compare to Definium Therapeutics?

Do institutionals & insiders have more ownership in PSNL or DFTX?

Which has more risk & volatility, PSNL or DFTX?

Does the media prefer PSNL or DFTX?

Do analysts prefer PSNL or DFTX?

Which has preferable valuation and earnings, PSNL or DFTX?

Is PSNL or DFTX more profitable?

Summary

How does Personalis compare to Surgery Partners?

Does the media favor PSNL or SGRY?

Which has better valuation and earnings, PSNL or SGRY?

Is PSNL or SGRY more profitable?

Which has more risk & volatility, PSNL or SGRY?

Do insiders & institutionals have more ownership in PSNL or SGRY?

Do analysts recommend PSNL or SGRY?

Summary

How does Personalis compare to Progyny?

Do institutionals & insiders have more ownership in PGNY or PSNL?

Do analysts recommend PGNY or PSNL?

Does the media favor PGNY or PSNL?

Which has preferable valuation & earnings, PGNY or PSNL?

Which has more risk and volatility, PGNY or PSNL?

Is PGNY or PSNL more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PSNL vs. The Competition

Personalis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools